The Role of Liver Biopsy in Hepatocellular Carcinoma.
作者信息
Finn Richard S
机构信息
Associate Professor of Medicine Department of Medicine Division of Hematology/Oncology Geffen School of Medicine at UCLA Los Angeles, California.
出版信息
Gastroenterol Hepatol (N Y). 2016 Oct;12(10):628-630.
Abstract
摘要
相似文献
1
The Role of Liver Biopsy in Hepatocellular Carcinoma.
Gastroenterol Hepatol (N Y). 2016 Oct;12(10):628-630.
2
Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study.
Gut. 2004 Sep;53(9):1356-62. doi: 10.1136/gut.2003.032359.
3
Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma.
AJR Am J Roentgenol. 1993 Aug;161(2):229-33. doi: 10.2214/ajr.161.2.8392785.
4
Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma.
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):813-29. doi: 10.1016/j.bpg.2014.08.012. Epub 2014 Aug 23.
5
Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma--a study based on 420 patients.
J Hepatol. 1996 Sep;25(3):334-8. doi: 10.1016/s0168-8278(96)80120-6.
6
Diagnosis of hepatocellular carcinoma complicating liver cirrhosis: utility of repeat ultrasound-guided biopsy after unsuccessful first sampling.
Cardiovasc Intervent Radiol. 2002 Jul-Aug;25(4):295-9. doi: 10.1007/s00270-001-0123-6. Epub 2002 Mar 27.
7
Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey--1974.
J Pediatr Surg. 1975 Jun;10(3):329-37. doi: 10.1016/0022-3468(75)90095-0.
8
Cytologic diagnosis of hepatocellular carcinoma by fine-needle aspiration biopsy.
Cancer. 1984 Feb 1;53(3):547-52. doi: 10.1002/1097-0142(19840201)53:3<547::aid-cncr2820530329>3.0.co;2-m.
9
All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus.
Clin Infect Dis. 2016 Feb 1;62(3):289-297. doi: 10.1093/cid/civ860. Epub 2015 Sep 28.
10
[A case of hepatocellular carcinoma diagnosed based on the result of a bone biopsy, in which the primary hepatocellular carcinoma was identified in the liver 14 months after the initial diagnosis].
Nihon Shokakibyo Gakkai Zasshi. 2011 May;108(5):805-12.
引用本文的文献
1
An Investigative Analysis of Therapeutic Strategies in Hepatocellular Carcinoma: A Raetrospective Examination of 23 Biopsy-Confirmed Cases Emphasizing the Significance of Histopathological Insights.
Cancers (Basel). 2024 May 17;16(10):1916. doi: 10.3390/cancers16101916.
2
Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review.
Cancers (Basel). 2022 Jul 11;14(14):3373. doi: 10.3390/cancers14143373.
3
Extracellular vesicles as a new hope for diagnosis and therapeutic intervention for hepatocellular carcinoma.
Cancer Med. 2021 Dec;10(23):8253-8271. doi: 10.1002/cam4.4370. Epub 2021 Oct 28.
4
Direct comparison of biopsy techniques for hepatic malignancies.
Clin Mol Hepatol. 2021 Apr;27(2):305-312. doi: 10.3350/cmh.2020.0301. Epub 2020 Dec 3.
5
Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis.
Clin Gastroenterol Hepatol. 2021 Aug;19(8):1679-1687. doi: 10.1016/j.cgh.2020.07.026. Epub 2020 Jul 18.
6
Establishment of hepatocellular carcinoma patient-derived xenografts from image-guided percutaneous biopsies.
Sci Rep. 2019 Jul 22;9(1):10546. doi: 10.1038/s41598-019-47104-9.
7
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.
Cancer Discov. 2019 Aug;9(8):1124-1141. doi: 10.1158/2159-8290.CD-19-0074. Epub 2019 Jun 11.
8
Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.
Gut Liver. 2019 May 15;13(3):342-348. doi: 10.5009/gnl18345.
本文引用的文献
1
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.
2
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Lancet Oncol. 2013 Jan;14(1):55-63. doi: 10.1016/S1470-2045(12)70490-4. Epub 2012 Nov 20.
3
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.
Cancer Cell. 2011 Mar 8;19(3):347-58. doi: 10.1016/j.ccr.2011.01.040.
4
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件